EVALUATING THE EFFECTIVENESS OF TARGETED LUNG CANCER THERAPY IN THE TURKESTAN REGION FOR 2019-2022
Introduction: The treatment of patients with lung cancer is one of the urgent problems of modern medicine. The detection of a mutation in the epidermal growth factor receptor gene (EGFR-Epidermal Growth Factor Receptor) is an important step in the treatment of widespread non-small cell lung cancer, since this approach consists in the fact that the use of specially developed targeted therapy drugs is clinically effective and allows you to identify a special group of patients. Research by scientists shows that the use of targeted therapy drugs in patients with disseminated non-small cell lung cancer and the presence of an EGFR mutation is clinically effective, as it leads to a significant increase in the frequency of objective effects and improved progression-free survival, compared with the results of chemotherapy.
Цель исследования. Evaluation of the effectiveness of targeted lung cancer therapy in the Turkestan region for 2019-2022.
Materials and methods: A retrospective statistical study of treatment results was conducted using the Kaplan-Meyer survival analysis and RECIST criteria. Patients were randomized (1:1) using a minimization procedure and stratified according to the type of EGFR mutation. The primary result was progression-free survival, analyzed in patients with confirmed disease who received at least a few doses of the investigational drug. During the study period, 96 patients with lung cancer with EGFR mutation were considered in the Turkestan region, 48 of them received targeted therapy (afatinib – 28 (58%) patients, erlotinib – 11 (58%) patients, osimertinib – 9 (58%) patients), and the remaining 48 received chemotherapy. The analyzed indicators were: patient's age, gender, histological data, diagnosis, stages, types of treatment. All statistical calculations were performed using the SPSS program (version 25.0, IBM SPSS Inc., Chicago, USA). The data were summarized using descriptive statistics methods.
Results: Thus, the median progression–free survival with afatanib is 12.6 months, with chemotherapy - 5.8 months. In patients taking afatinib, progression is observed 0.266.67 times less frequently than in patients receiving chemotherapy, since the confidence interval does not contain 1, the relationship between taking afatinib and the time of onset of progression is statistically significant (p<0.05). That is, the median progression-free survival was significantly higher in patients receiving erlotinib than in patients receiving chemotherapy (12.6 vs. 5.8 months; HR=0.26667, 95% CI 0.10088–0.703733; p< 0.05).
The median progression–free survival with erlotinib is 13.8 months, with chemotherapy - 4.8 months.In patients receiving erlotinib, progression is 0.2223 times less frequent than in patients receiving chemotherapy, then the relationship between taking erlotinib and the time of onset of progression is statistically significant (p<0.05). That is, the median progression-free survival was significantly higher in patients receiving erlotinib than in patients receiving chemotherapy (13.8 versus 5.8 months; HR=0.22223, 95% CI 0.187457–0.932733; p< 0.05). The median progression–free survival with osimertinib is 10 months, with chemotherapy - 4.6 months. In patients taking the drug osimertinib, progression is observed 0.42857 times less frequently than in patients receiving chemotherapy, the relationship between taking osimertinib and the time of onset of progression is statistically significant (p<0.05). That is, the median progression-free survival was significantly higher in patients receiving osimertinib than in patients receiving chemotherapy (10 vs. 4.6 months; HR=0.42857, 95% CI 0.161232–0.737965; p< 0,05).
Conclusion: The effectiveness of targeted lung cancer therapy in the Turkestan region for 2019-2022 was evaluated for the first time. The progression of the process was observed in 6 (13%) patients receiving targeted therapy, stabilization of the process was observed in 33 (68%) patients, and partial regression was observed in 9 (19%) patients. The stabilization of the process was 68%, that is, it lasted for more than 12 months. It should be noted that, compared with standard chemotherapy, targeted therapy provided a significant improvement in progression-free survival in patients with advanced non-small cell lung cancer with an EGFR mutation and was associated with more favorable tolerability.
Zhanar S. Tumenbayeva1, https://orcid.org/0009-0004-9104-8954
Abai K. Makishev2, https://orcid.org/0000-0001-9874-4005
1 South Kazakhstan Medical Academy, Shymkent, Republic of Kazakhstan;
2 NJSC «Astana Medical University», Astana, Republic of Kazakhstan.
1. Кайдарова Д.Р., Балтабекова Н.Т., Душимова З.Д. и др. Показатели онкологической службы Республики Казахстан за 2019 – 09.02.2021 годы (статистические и аналитические материалы), Almaty. https://onco.kz/Pokazateli-onkologicheskoj-sluzhby-Respubliki-Kazahstan-za-2019-g_09.02.2021_compressed-1.pdf. (Дата обращения 01.04.2023)
2. Клинический протокол диагностики и лечения рака легкого от 01.07.2022г., №164. (Дата обращения 17.05.2023)https://diseases.medelement.com/
3. Bailey-Wilson J.E., Amos C.I., Pinney S.M. et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. // J Hum Genet 2004. 75(3):460–474.
4. Brierley J., Gospodarowicz M.K., Wittekind C. Union for International Cancer Control. TNM Classification of Malignant Tumours 8th edition,1-241
5. City J., Buffett P. What proportion of lung cancer in non-smokers can be attributed to known risk factors? // Int J Cancer. 2012. 131 (2): 265–275. DOI: 10.1002 / ijc.27477
6. Chen G., Feng J., Zhou C., et al. Quality of life (Qol) analyses from Optimal (CTONG-0802), a phase III, randomized,open-label study of first – line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positiv non-small-cell lung cancer (NSCLC) // Annals of oncology. 2013. 24: 1615–1622.
7. Chen N., Fang W., Zhan J. [et al.] Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation // J Thorac Oncol. 2015. Vol. 6. №10. P. 910-923.
8. El Тelbani A., Ma P.C. Cancer genes in lung cancer: racial differences: are there? // Cancer genes. 2012. 3 (7–8): 467–480. DOI: 10.1177 / 1947601912465177
9. Fujikawa A., Takiguchi Y., Mizuno S., et al. Lung cancer screening - comparison of computed tomography and radiography // Lung cancer. 2008. 61 (2): 195–201. DOI: 10.1016 / j. lungcan.2007.12.010
10. Goldstraw P., Ball D., Jett J.R. et al. Non-small-cell lung cancer // Lancet, 2011. 378: 1727–40.
11. Greenhalgh J., Boland A., Bates V., Vecchio F., Dundar Y., Chaplin M., Green J.A. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer // Cochrane Database Syst Rev. 2021 Mar 1. 3(3):CD010383. doi: 10.1002/14651858.CD010383.pub3.
12. Gridelli C., Rossi A., et al. EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population // J Thorac Dis.- 2012. 4(2): 219–220.
13. Janne P.A.,Yang J.S., Kim D.W. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer // N Engl J Med. 2015. 372:1700-1709.
14. Kalemkerian G.P. et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update // J Clin Oncol. 2018.Vol. 9. №36. P. 911-919.
15. Kang H.R., ChOj.Y., Li Sh. et al. The role of low-dose computed tomography in screening for lung cancer in non-smokers // J Thorac Oncol. 2019. 14 (3): 436–444. DOI: 10.1016 / j. jtho.2018.11.002
16. Li C., Jia R., Liu H. et al. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors // Diagn. Pathol. 2018. Vol. 13. №1. P. 49.
17. Lin L., Li Z., Yan L., Liu Y., Yang H., Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019 // J Hematol Oncol. 2021 Nov. 22. 14(1):197. doi: 10.1186/s13045-021-01213-z.
18. Maemondo M., Inoue A., Kobayashi K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR // N. Engl. J. Med 2010, 362(25): 2380–8.
19. Mendelson J., aselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer //Journal Clinical Oncology. 2003. Vol.21. P.2787-99.
20. Midcha A., Dirden S., McCormack R. Prevalence of EGFR mutation in non-small cell lung cancer in adenocarcinoma histology: a systematic review and a global map by ethnicity (mutMapII) // J Cancer Res. 2015; 5 (9): 2892–2911.
21. Mok TS, Wu Y, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma // N Engl // J Med 2009. 361: 947–957.
22. Murray S., Dahabreh I.J., Linardou H., et al.Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer:an analytical database // J Thorac Oncol. 2008. 3:832-839.
23. Nicholson A.G. [et al.] Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis // J Thorac Oncol. 2010. Vol. 4. №5. P. 436-441.
24. Novello S. [et al.] Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. 2016. №27. Suppl 5. P. v1-v27.
25. Pirker R. [et al.] Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop // J Thorac Oncol. 2010. Vol. 10. №5. P. 1706-1713.
26. Planchard D., Popat S., Kerr K. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. 2018. 29(Suppl 5): iv192–iv237.
27. Sequist L.V., Martins R.G., Spigel D. et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations// J Clin Oncol. 2008. 26: 2442–2449.
28. Siegelin M.D., Borczuk A.C. Epidermal growth factor receptor mutations in lung adenocarcinoma // Lab Invest. 2014. Vol. 2. №94. P. 129-137.
29. Shepherd F., Pereira J., Cinleanu T.E., et al. Erlotinib in previously treated non-small cell lung cancer // N. Engl. J.Med. 2005, 353:123-32.
30. Soria J.-C., Ohe Y., Vansteenkiste J. et al. FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer // N. Engl. J. Med.-2018. Vol. 378. № 2. P. 113–125.
31. Sun Y., Ren Y., Fang Z. et al. Lung adenocarcinoma in never-smokers from East Asia is a disease largely determined by guided oncogenic mutant kinases // J Clin Oncol. 2010. 28 (30): 4616–4620. DOI:10.1200/JCO.2010.29.6038
32. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J. Clin. 2021: 71: 209-249. https://doi.org/10.3322/caac.21660
33. Timofeeva M.N., Hung J., Rafnar T. et al. The effect of common genetic variations on lung cancer risk: meta-analysis of 14,900 cases and 29,485 controls // Hum Mol Genet. 2012. 21 (22): 4980-4995. DOI: 10.1093/hmg/dds334
34. Torre L.A., Bray F., Siegel R.L. et al. Global cancer statistics, 2012 // CA Cancer J Clin. 2015. 65:87–108.
35. Warth A. [et al.] Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies // Histopathology. 2012. Vol. 6. №61. P. 1017-1025.
36. Yang J.C., Sequist L.V., Geater S.L. et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 // Lancet Oncol. 2015. Vol.7. №16. P. 830-838.
37. Yang V., Qian F, Teng J, et al. Community-based lung cancer screening with low-dose CT in China: results of basic screening // Lung cancer. 2018. 117: 20–26. DOI: 10.1016 / j. lungcan.2018.01.003
References: [1]
1. Kaidarova D.R., Baltabekova N.T., Dushimova Z.D. i dr. Pokazateli onkologicheskoi sluzhby Respubliki Kazakhstan za 2019-09.02.2021 gody (statisticheskie i analiticheskie materialy) [Indicators of the oncological service of the Republic of Kazakhstan for 2019 - 09.02.2021 (statistical and analytical materials)], Almaty. https://Pokazateli-onkologicheskoj-sluzhby-Respubliki-Kazahstan-za-2019-g_09.02.2021_compressed-1.pdf (accessed 01.04.2023) [in Russian]
2. Klinicheskii protokol diagnostiki i lecheniya raka legkogo [Clinical protocol for the diagnosis and treatment of lung cancer] ot 01.07.2022g., №164. (accessed 17.05.2023) https://diseases.medelement.com/ [in Russian]
Number of Views: 228
Category of articles:
Original articles
Bibliography link
Tumenbayeva Zh.S., Makishev A.K. Evaluating the effectiveness of targeted lung cancer therapy in the Turkestan region for 2019-2022 // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 6, pp. 30-37. doi 10.34689/SH.2023.25.6.004Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS